When combined with results from the in vitro study by Liu and colleagues [62], our in vivo results suggest one mechanism by which STAT3 inhibition attenuates amyloid pathogenesis and its associated neurovascular deficits is by attenuating APP processing through inhibition of BACE1 activity. The gene discussed is APP; the disease is amyloidosis.